Navigation Links
Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
Date:4/30/2008

SAN BRUNO, CA, April 30 C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. A new report released this month by the federal Agency for Healthcare Research and Quality revealed a 200 percent increase in potentially fatal diarrheal infections in U.S. hospitals between 2000 and 2005. Additionally, the Association for Professionals in Infection Control and Epidemiology (APIC) is launching the first national prevalence study for C. diff beginning May 1.

According to Patricia Raymond, MD, FACP, FACG, a Chesapeake, Virginia-based gastroenterologist, associate professor of clinical medicine at Eastern Virginia Medical School and host of the soon-to-be-launched Your Health Choice radio program, traditional treatment for C. diff-associated disease is the use of powerful antibiotics such as metronidazole or vancomycin, but one of the most troublesome aspects of the disease is its high rate of recurrence. But studies show that adding the yeast-based probiotic Saccharomyces boulardii (sold under the brand name Florastor®), can cut the rate of recurrence by about half.

Almost one in four CDAD patients will experience a recurrence of symptoms after a round of antibiotic therapy alone, says Dr. Raymond. C. difficile colitis has been in the news recently as more virulent strains are emerging. These more toxic bugs lead to higher rates of surgery for colon removal and death from the infection. Doctors are using everything in their toolboxes to combat C. difficile, and one of our proven tools is Saccharomyces boulardii. When a relapse occurs, use of Florastor during the antibiotic course can help protect against future relapses.

A recent meta-analysis of 31 studies compiled and published in the American Journal of Gastroenterology concluded that S. boulardii is the only probio
'/>"/>

Contact: Christina Occhipinti
cocchipinti@robinleedyassociates.com
914-241-0086
Biocodex, Inc.
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
4. BASF Podcast: The Chemical Reporter - Why do You Get Garlic Breath?
5. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
6. Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk)
7. Mindray to Report First Quarter 2008 Financial Results on May 7, 2008
8. Kensey Nash Reports Third Quarter Record Revenue and Sales
9. Webcast Alert: HCA announces HCA 1Q 2008 Earnings Report
10. Landauer, Inc. Reports Record Results for Second Quarter
11. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...nhibOx, a leading developer of novel and effective...ned forces with MolPort, an innovator in rare chem...hemical trading platform and builds database of co...s database and its updates to computational chemis...irtual screening procedures. Once they identify su...
(Date:12/4/2009)...st-Selling author and Personal & Organizationa...Transformation through Accountability! , ...4, 2009 -- IMPAQ Accountability Business Consult...est-selling Author, renowned Speaker, and CEO &...ants Inc., will present at the 14th International ...
(Date:12/3/2009)...iropractic Traffic has gotten into the holiday spi...rketing tool. $1 gets chiropractors 3 months of un... Traffic is even including chiropractic promotiona... (PRWEB) December 3, 2009 -- Chiropractic Marke...tool. Chiropractic Marketing expertise provided b...
(Date:12/3/2009)...., Dec. 3 The development of Unive...MCPP) reached a milestone today with a "topping ou... construction at the new hospital that will replac..., (Photo: http://www.newscom.com/cgi-bin/prnh/... a steelworkers, tradition in which a steel beam c...
(Date:12/3/2009)... The American Medical A...tates District Court for the Southern District of ...reviously disclosed $350 million settlement that w...Health Group. ,, The action brought by the AMA,...ouri State Medical Association, along with several...
Breaking Medicine News(10 mins):Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3Health News:Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference 2Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 3Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 4Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2
... 26 days across deserts and mountains, a group of ...oss-country motorbike// expedition to spread aware...ebruary 26 from Bangalore, Karnataka, the group of...in other such expeditions before but they have bee...
...ildhood could fall victims to other types of cance... Early attention and prompt treatment could help...es more likely to develop other types of cancers t...ute lymphoblastic leukemia as children and adolesc...
...ng center and cervical cancer screening program wi...rba Gandhi Hospital// (KGH) at Chennai, capital of... to determine the cause of abnormalities found in ...ican anatomist. It is used to detect changes that ...
...ave demanded a commitment for more funding if talk...nt review of the NHS Wheelchair// and Seating Serv...0m a year. But the Scottish Executive has agreed a... too lightly. Meanwhile BBC Scotland has come to u...
... been established at Kattankulathur, off Chennai, ...//. It will be functioning as part of the SRM Med.... Sathyanarayanan, Vice Chancellor, SRM University... It would commence from the academic year 20...
...tte smoking may actually aid in decreasing the ris...quential association// between smoking and reduced...s conducted by Evan L. Thacker and colleagues from...ibilities of neuro-protective chemicals that may b...
Other Medicine News:Health News:Cross-country Mobike Expedition to Spread AIDS Awareness 2Health News:New School of Public Health in Chennai 2
(Date:12/3/2009)..., , PISCATAWAY, N.J., Dec. 3 /PRNewswir...letin Board: MLSS), the recognized leader in advan...t had entered into a joint venture with China Nati...) and Yichang Humanwell Pharmaceutical Co. Ltd., b... (the "PRC"), to develop orthopedic and epidural d...
(Date:12/3/2009)..., , WALTHAM, Mass., Dec. 3 /PRNewswire...ing research and advisory firms focusing on pharma... type 2 diabetes drug market in Brazil will grow f...The projected 15 percent annual growth rate is att...pulation, increased use of new generation antidiab...
(Date:12/3/2009)..., , SAN DIEGO, Dec. 3 Amir...sitive data from a Phase 1 clinical study of AM461...f the DP2 (also known as CRTH2) receptor. ,, ...tional pharmacodynamic (PD) effect can be achieved...date demonstrates a good safety profile. AM461 is...
Breaking Medicine Technology:Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 1BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 2BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program 47480 3Record 73 4 Million Pounds Collected in Letter Carriers National Food Drive 47476 1Record 73 4 Million Pounds Collected in Letter Carriers National Food Drive 47476 2Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 1Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 2Kendle Expands Asia Pacific Operations with Opening of Offices in Kuala Lumpur Bangkok and Manila 12390 3
...at Tufts Medical Center have created a formula for... certain genetic profiles and lifestyle behaviors ...tion (AMD), a potentially blinding condition that ...mericans and is increasing dramatically as the pop...eddon, MD, ScM, Professor of Ophthalmology at Tuf...
...44th Annual Meeting of EASL , , Management to Dis...nancial Results Call at 5 P.M. EDT Today , , SAN...sdaq: ANDS ) today announced that ANA598, the Co...inhibitor, demonstrated potent antiviral activity ...se Ib study in which patients chronically infected...
Other Medicine Technology:Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD) 2ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 2ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 3ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 4ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 5ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 6ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 7ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients 8
... A Test gives your laboratory clear-cut results in...icile, you can't afford to wait. For any laborator...t its suspected C. difficile samples for testing, ...ill cut costs and minimize your time-to-results wh...
Clearview C DIFF A
...ion, accuracy and easy operation TOMEYs patented l...viding high resolution. The laser alignment system... cone design eliminates nose & brow shadow & provi...l of the rings promotes patient comfort. New TMS S...
Pachycam
Medicine Products: